243 related articles for article (PubMed ID: 29054321)
1. Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.
Sendra C; Silva Ruiz MDP; Ferrer Rios MT; Alarcón García JC; Pascasio Acevedo JM
Gastroenterol Hepatol; 2018; 41(7):440-441. PubMed ID: 29054321
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
4. Vasoconstrictors in hepatorenal syndrome - A critical review.
Mattos ÂZ; Schacher FC; Mattos AA
Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Nanda A; Reddy R; Safraz H; Salameh H; Singal AK
J Clin Gastroenterol; 2018 Apr; 52(4):360-367. PubMed ID: 28991106
[TBL] [Abstract][Full Text] [Related]
6. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Thomson MJ; Taylor A; Sharma P; Lok AS; Tapper EB
Dig Dis Sci; 2020 May; 65(5):1539-1548. PubMed ID: 31571102
[TBL] [Abstract][Full Text] [Related]
7. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
8. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
Saif RU; Dar HA; Sofi SM; Andrabi MS; Javid G; Zargar SA
Indian J Gastroenterol; 2018 Sep; 37(5):424-429. PubMed ID: 30178092
[TBL] [Abstract][Full Text] [Related]
9. Hepatorenal syndrome: Current concepts related to diagnosis and management.
de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
11. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
12. Management of hepatorenal syndrome and associated outcomes: a systematic reviews.
Roozbeh J; Ezzatzadegan Jahromi S; Rezazadeh MH; Hamidianjahromi A; Malekmakan L
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38631807
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
16. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.
Schmidt LE; Ring-Larsen H
Curr Pharm Des; 2006; 12(35):4637-47. PubMed ID: 17168767
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
Kalambokis GN; Christaki M; Tsiakas I; Despotis G; Milionis HJ
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1292-1294. PubMed ID: 31498285
[No Abstract] [Full Text] [Related]
18. Terlipressin in the management of liver disease.
Scheinberg AR; Martin P; Turkeltaub JA
Expert Opin Pharmacother; 2023; 24(15):1665-1671. PubMed ID: 37535437
[TBL] [Abstract][Full Text] [Related]
19. The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Pitre T; Kiflen M; Helmeczi W; Dionne JC; Rewa O; Bagshaw SM; Needham-Nethercott N; Alhazzani W; Zeraatkar D; Rochwerg B
Crit Care Med; 2022 Oct; 50(10):1419-1429. PubMed ID: 35777925
[TBL] [Abstract][Full Text] [Related]
20. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
